Central Nervous System News and Research

RSS

Multi-resistant CNS bacteria spread in Sweden hospitals

Genetically closely related skin bacteria that have developed resistance to several different antibiotics and that can cause intractable care-related infections are found and seem to be spreading within and between hospitals in Sweden.

9 Sep 2010

Ohio State University receives five-year grant to improve drug therapy using gene profiles

The National Institute of General Medical Sciences has awarded a $9.1 million, five-year grant to The Ohio State University for a study titled "Expression Genetics in Drug Therapy." The goal of the research is to enhance drug response rates and reduce the number of adverse drug reactions among patients taking medication.

9 Sep 2010

PPD establishes preferred provider relationships for conducting Phase I trials

PPD, Inc. today announced it has established preferred provider relationships with a network of sites across North America for conducting Phase I trials in patients to meet growing client demand for these services.

8 Sep 2010

Bayer Consumer Care introduces One A Day Menopause Formula to help address hot flashes

September is Menopause Awareness Month and women starting the transition into menopause have more information and resources than ever to start taking control of their menopause symptoms. Bayer Consumer Care now introduces One A Day® Menopause Formula, a complete multivitamin with soy isoflavones to help address hot flashes and mild mood changes.

7 Sep 2010

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).

7 Sep 2010

Studies show diagnostic errors cause adverse events than medication errors

Studies show that diagnostic errors cause twice as many adverse events as medication errors, but the subject has received little attention; Pennsylvania Patient Safety Authority reviews 100 events related to diagnostic error.

3 Sep 2010

Research on motor neuron subtype may provide useful therapy for neuron diseases

Scientists have devised a method for coaxing mouse embryonic stem cells into forming a highly specific motor neuron subtype. The research, published by Cell Press in the September 3rd issue of the journal Cell Stem Cell, provides new insight into motor neuron differentiation and may prove useful for devising and testing future therapies for motor neuron diseases.

3 Sep 2010

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry Letters on the anti-tumor activity of RX-8243 and its analogues.

3 Sep 2010

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list for depression treatment

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical stage candidate for the treatment of depression, GLYX-13, and its second-generation NRX-1050 series have been selected for inclusion on Windhover's list of the "Top 10 Most Interesting Neuroscience Projects to Watch."

31 Aug 2010

TPP and University of Edinburgh collaborate on development of novel pre-clinical intellectual property

TPP Global Development Ltd (TPP) announced an agreement with the University of Edinburgh to collaborate on the development of novel pre-clinical intellectual property originated within the University.

31 Aug 2010

SIR issues position statement to determine safety, effectiveness of interventional M.S. treatment

Recognizing that venous interventions may potentially play an important role in treating some patients who suffer from multiple sclerosis an incurable, disabling disease the Society of Interventional Radiology has issued a position statement indicating its support for high quality clinical research to determine the safety and effectiveness of interventional M.S. treatments.

31 Aug 2010

Cognizant Communication launches 'Cell Medicine' open access journal

A new and unique journal on cell transplantation aimed at helping translate laboratory findings into clinical applications is being launched by Cognizant Communication Corporation as a companion journal to Cell Transplantation. Cell Medicine, an online-only, open access journal, publishes research papers that promise to have direct clinical relevance. The journal is freely accessible at: http://www.ingentaconnect.com/content/cog/cm.

30 Aug 2010

Latest achievements in brain research and treatment for mental disorders

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

30 Aug 2010

'Neural inertia' may explain brain's resistance to changes in consciousness

Despite the fact that an estimated 25 million patients per year in the U.S. undergo surgeries using general anesthesia, scientists have only been able to hypothesize exactly how anesthetics interact with the central nervous system. They previously thought that the processes of "going under" and waking up from anesthesia affected the brain in the same way.

27 Aug 2010

Researchers recommend traumatic brain injury reclassification for additional funding

Traumatic brain injury, currently considered a singular event by the insurance industry and many health care providers, is instead the beginning of an ongoing process that impacts multiple organ systems and may cause or accelerate other diseases and disorders that can reduce life expectancy, according to research from the University of Texas Medical Branch at Galveston.

27 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

26 Aug 2010

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecule compounds that target P2X3 receptors, today announced preclinical in vivo results demonstrating that an investigational P2X3 receptor antagonist reduced experimentally induced bladder hyperactivity.

26 Aug 2010

Aileron Therapeutics, Roche partner to develop, commercialise Stapled Peptide Therapeutics

Aileron Therapeutics and Roche announced today that they have entered into a collaboration to discover, develop and commercialise a new class of drugs called Stapled Peptide Therapeutics. As part of this agreement, Roche will work with Aileron to develop drug candidates against up to five undisclosed targets selected from Roche's key therapeutic areas, which include oncology, virology, inflammation, metabolism and CNS.

24 Aug 2010

Alpha-synuclein gene silencing effective for treating neurodegenerative disorders: Research

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.

24 Aug 2010

Human neural stem cells restore motor function in mice with chronic spinal cord injury

StemCells, Inc. announced today the publication of new preclinical data demonstrating that the Company's proprietary human neural stem cells restore lost motor function in mice with chronic spinal cord injury. This is the first published study to show that human neural stem cells can restore mobility even when administered at time points beyond the acute phase of trauma, suggesting the prospect of treating a much broader population of injured patients than previously demonstrated.

20 Aug 2010

Central Nervous System News and Research

Multi-resistant CNS bacteria spread in Sweden hospitals

Ohio State University receives five-year grant to improve drug therapy using gene profiles

PPD establishes preferred provider relationships for conducting Phase I trials

Bayer Consumer Care introduces One A Day Menopause Formula to help address hot flashes

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Studies show diagnostic errors cause adverse events than medication errors

Research on motor neuron subtype may provide useful therapy for neuron diseases

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list for depression treatment

TPP and University of Edinburgh collaborate on development of novel pre-clinical intellectual property

SIR issues position statement to determine safety, effectiveness of interventional M.S. treatment

Cognizant Communication launches 'Cell Medicine' open access journal

Latest achievements in brain research and treatment for mental disorders

'Neural inertia' may explain brain's resistance to changes in consciousness

Researchers recommend traumatic brain injury reclassification for additional funding

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Aileron Therapeutics, Roche partner to develop, commercialise Stapled Peptide Therapeutics

Alpha-synuclein gene silencing effective for treating neurodegenerative disorders: Research

Human neural stem cells restore motor function in mice with chronic spinal cord injury

Event guide: The 7th CNS Drug Delivery Summit eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News